Sensitivity and Specificity - you can not have one without the other
Quote:
Originally Posted by
MAC
...Cxbladder clinically outperforms all other tests within this first market, and because it has high sensitivity, 100% for most early stage tumors, it is a much lower litigation risk, and will demand a price point in commensuration of those two reasons....
I was of the impression that most early stage tumors were Ta tumors and the clinical trial results state that CxBladder has a sensitivity of 68% for these. [The numbers imply that in the tests about 57% of all the tumors were Ta].
For the remaining 43% (which includes Tis early stage) then the study does state a sensitivity of 100%.
The flip side of this is the low overall specificity of 85%.
Best Wishes
Paper Tiger